IQUIX
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IQUIX is an ophthalmic solution approved in 2004 for treatment of eye conditions. The exact mechanism of action and clinical indications are not specified in available data, but the product is administered as eye drops. As a small-molecule ophthalmic agent, it represents a mature therapeutic option in its indication area.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential headcount restructuring on the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IQUIX roles are concentrated in Commercial and Finance departments, reflecting sponsor Santen's Asia-Pacific focus and the product's mature lifecycle stage. Career opportunities emphasize financial planning, safety compliance, and regional commercial execution rather than innovation or development.
[Singapore] Head of FP&A[Singapore] Global Safety Vigilance Risk Management Lead
Worked on IQUIX at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.